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ABSTRACT
Objective: To investigate the genetic and physiologic basis of the neuromuscular symptoms of
hypotonia-cystinuria syndrome (HCS) and isolated PREPL deficiency, and their response to
therapy.
Methods: We performed molecular genetic, histochemical, immunoblot, and ultrastructural stud-
ies, investigated neuromuscular transmission in vitro in a patient with isolated PREPL deficiency,
and evaluated the effect of pyridostigmine in this patient and in 3 patients with the HCS.
Results: HCS is caused by recessive deletions involving the SLC3A1 and PREPL genes. The major
clinical features of HCS are type A cystinuria, growth hormone deficiency, muscle weakness,
ptosis, and feeding problems. The proband with isolated PREPL deficiency had myasthenic symp-
toms since birth and a positive edrophonium test but no cystinuria. She and 1 of 3 patients with
HCS responded transiently to pyridostigmine during infancy. The proband harbors a paternally
inherited nonsense mutation in PREPL and a maternally inherited deletion involving both PREPL
and SLC3A1; therefore, the PREPL deficiency determines the phenotype. We detected no PREPL
expression in the patient’s muscle and endplates. Electrophysiology studies revealed decreased
quantal content of the endplate potential and reduced amplitude of the miniature endplate poten-
tial without endplate acetylcholine receptor deficiency or altered endplate geometry.
Conclusion: Isolated PREPL deficiency is a novel monogenic disorder that causes a congenital
myasthenic syndrome with pre- and postsynaptic features and growth hormone deficiency. The
myasthenic symptoms in PREPL deficiency with or without cystinuria may respond to pyridostig-
mine in early life. We attribute the myasthenia to abrogated interaction of PREPL with adaptor
protein 1. Neurology® 2014;82:1–7
GLOSSARY
ACh 5 acetylcholine; AChR 5 acetylcholine receptor; AP-1 5 adaptor protein 1; bp 5 base pair; cDNA 5 complementary
DNA; EP 5 endplate; EPP 5 endplate potential; HCS 5 hypotonia-cystinuria syndrome; IGF 5 insulin-like growth factor;
MEPC 5 miniature endplate current; MEPP 5 miniature endplate potential; OMIM 5 Online Mendelian Inheritance in Man;
SNARE 5 soluble N-ethylmaleimide-sensitive factor atachment protein receptor.
The hypotonia-cystinuria syndrome (HCS) (Online Mendelian Inheritance in Man [OMIM] #
606407) is characterized by cystinuria in combination with severe neonatal hypotonia, fluctu-
ating ptosis, facial paresis, dysarthria and feeding problems suggesting a myasthenic disorder,
and growth hormone deficiency. Other features are viscous saliva and hypergonadotrophic
hypogonadism, and half of the patients need special education.1,2 The hypotonia and feeding
problems improve during the first year of life, but ptosis, nasal voice, dysarthria, facial weakness,
and mild axial and proximal muscle weakness persist. Hyperphagia with tendency to obesity
develops during childhood. HCS is caused by autosomal recessive deletions involving 2 con-
tiguous genes on chromosome 2p21: SLC3A1, which encodes the heavy subunit of the cystine
dibasic and neutral amino acid transporter (OMIM * 104614), and PREPL, the prolyl
endopeptidase-like gene (OMIM * 609557) (figure 1G). Seventeen HCS families with 9 dif-
ferent deletions ranging from 23.8 to 127.2 kb have been reported to date.1–4
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Recessive deletion syndromes involving more
genes at the 2p21 chromosomal region have
been described.5–7 These are clinically different
and more severe, probably because of mito-
chondrial involvement. When C2orf34, distal
to PREPL, is involved, the syndrome is referred
to as atypical HCS, and when PPM1B, proxi-
mal to SLC3A1, is also involved, the syndrome
is designated as 2p21 deletion syndrome.
PREPL is ubiquitously expressed, with
highest levels in brain, kidney, and muscle,
in decreasing order.8 Because mutations in
SLC3A1 cause isolated cystinuria type A, we
hypothesized that the neuromuscular and
other noncystinuric manifestations of HCS
are caused by PREPL deficiency.1,7 In atypical
HCS, the involvement of SLC3A1 is only
responsible for cystinuria, because the pheno-
type associated with a deletion restricted to
PREPL and C2orf34 is very similar to that of
atypical HCS but without cystinuria.9
Herein, we report a patient with isolated
PREPL deficiency, show it causes a novel
myasthenic syndrome, elucidate its structural
and electrophysiologic features, and assess
the effects of pyridostigmine treatment in this
patient as well as in 3 patients with the HCS.
METHODS Standard protocol approvals, registrations,
and patient consents. The human studies reported herein were
approved by the Institutional Review Boards of the Hospitals of
Leuven University and the Mayo Clinic, and each participant or
their parent gave informed consent to participate in the study.
Molecular genetics. Total blood RNA was obtained with the
PAXgene system (Qiagen Benelux, Venlo, the Netherlands).
Complementary DNA (cDNA) was produced from RNA tem-
plates with the iScript Select cDNA synthesis kit (Bio-Rad Labo-
ratories, Nazareth, Belgium). Genomic DNA was isolated from
blood by routine techniques. The combined deletion of PREPL
and SLC3A1 was detected by microarray-based comparative
genomic hybridization performed by Athena Diagnostics
(Worcester, MA). To map the borders of the deletion, we used
quantitative PCR with different primer sets around the predicted
borders of the deletion. A junction fragment was then amplified
by standard PCR techniques. To formally prove heterozygosity,
we chose different primer sets to amplify either the junction
fragment or the normal allele (primers available on request).
Sanger sequencing was used to sequence PREPL cDNA,
genomic DNA, and the junction fragment. The reference
sequence was GRCh37, NM_006036.4.
PREPL expression monitored by immunoblotting and
immunohistochemistry. Extracts of frozen muscle from
patient and control specimens were prepared for immunoblotting
as previously described.10 After transfer to nitrocellulose mem-
brane (Life Technologies, Carlsbad, CA), the blots were probed
at 1:200 dilution with a mouse monoclonal antibody (Santa Cruz
Biotechnology, Dallas, TX) directed against a C-terminal PREPL
epitope, and the bands were detected with an appropriate second-
ary antibody as described.11 We immunolocalized PREPL in fro-
zen sections of muscle harboring endplates (EPs) with the same
antibody at 1:20 dilution and with a DyLight 488 (green) anti-
mouse second antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA) at 1:200 dilution. PREPL expression at the EPs
was ascertained by colocalization with rhodamine-labeled
a-bungarotoxin.12
EP studies. These were performed on the anconeus muscle. Ace-
tylcholinesterase and the acetylcholine receptor (AChR) were
localized in frozen sections as previously described.12 EPs were
localized for electron microscopy and quantitatively analyzed by
established methods.13 Peroxidase-labeled a-bungarotoxin was
used for the ultrastructural localization of AChR.14 The number
of AChRs per EP was measured with [125I]a-bungarotoxin.15
The miniature EP potential (MEPP), miniature EP current
(MEPC), and EP potential (EPP) amplitudes and the number of
quanta released by nerve impulse (m) were measured as previously
reported.16–18 The number of quanta available for release (n), and
the probability of quantal release (p) were determined as previously
described.19
Evaluation of response of patients with HCS to
pyridostigmine. An infant (HCS1) was evaluated using the
Alberta Infant Motor Scale and 2 older patients (HCS2 and
HCS3) with the 6-Minute Walk Test, handheld myometry of
selected muscle groups, maximal inspiratory and expiratory pres-
sures, and video-recordings of ptosis and speech. To exclude
spontaneous improvement or training effects, we stopped the
pyridostigmine for at least 24 hours before reevaluating the
patients.
RESULTS Clinical data. The patient with isolated
PREPL deficiency was born after 39 weeks of gestation.
Her birth weight was normal, but she had marked hypo-
tonia and feeding difficulties. At age 11 weeks, she had
eyelid ptosis, a tented upper lip, proximal-predominant
muscle weakness that varied during the day, normal
tendon reflexes, and a strongly positive response to
edrophonium and pyridostigmine (figure 1, C and D).
She had a normal metabolic workup, no cystinuria, and
a normal brain MRI. Tests for anti-AChR and anti-
MuSK antibodies were negative. She was treated with
pyridostigmine and discharged with a nasogastric tube
that was later changed to a J-tube. At age 6 months, she
was further investigated at the Mayo Clinic. She was still
markedly hypotonic (figure 1, A and B). EMG studies
when not taking pyridostigmine showed no decrement
at 2 Hz, a finding also noted in myasthenic infants
whose small muscle fibers have an increased input
resistance.17 She continued to improve and was
weaned off pyridostigmine at age 12 months without
deterioration. She walked at 17 months, but her gait was
waddling and she preferred using a walker. Language
development was normal. The serum insulin-like
growth factor (IGF)-1 level was repeatedly low (,25
ng/mL), but the level of its binding protein IGFBP-3
was normal (1.5 mg/mL), and a growth hormone
stimulation test showed growth hormone deficiency,
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indicating that these features of HCS are caused by the
PREPL deficiency.
We also treated 3 previously identified patients
with HCS (for clinical and genetic features, see table
e-1 on the Neurology® Web site at Neurology.org), at
1,2 11,1 and 121 years of age with pyridostigmine.
Only the infant improved, with an impressive
change in the Alberta Infant Motor Scale score
within a day, but, similar to the infant with isolated
PREPL deficiency, there was no deterioration when
pyridostigmine was stopped 2 months later (see figure
e-1). The 2 older children did not respond to
pyridostigmine.
Molecular genetics. Microarray-based comparative
genomic hybridization detected a heterozygous dele-
tion in the patient at 2p21 estimated to encompass
base pairs (bp) 44524771–44557935. Quantitative
PCR confirmed the deletion and showed the same
deletion in the mother. To fine-map the deletion,
Figure 1 Clinical and genetic features
(A, B) Patient at age 6 months. Note marked hypotonia with frog-leg posture and head drop. (C, D) Positive response to pyr-
idostigmine at age 11 weeks. (E) PCR fragments in the patient, the parents, and a control. Upper lane: junction fragment,
present only in the patient and her mother; middle lane: PCR with forward primer in the nondeleted and reverse primer in
the deleted region of SLC3A1; lower lane: PCR with forward primer in the deleted and reverse primer in the nondeleted
region of PREPL. Only the normal allele will produce a band in the 2 lower lanes. (F) Sequence chromatograms show a single
base pair (bp) deletion (first bp after the vertical bar) in the patient’s genomic DNA (gDNA) and complementary DNA (cDNA)
and in the father’s gDNA and cDNA, not present in the mother. cDNA primers were designed to amplify only the nondeleted
allele so that only the paternal allele is sequenced in the patient’s cDNA, clearly demonstrating the single bp deletion. (G)
Overview of 2p21 region showing the identified deletions. The patient with isolated PREPL deficiency was compound
heterozygous for the nonsense mutation (red arrow) and deletion J. Deletions A, B, and H were homozygous in the patients
with hypotonia-cystinuria syndrome.
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we generated and sequenced a junction fragment
(figure 1E) and found a novel deletion, CAGGATCT
CCTTCTGCCA (44525557) . (44559126) CCC
AGGCTGGAGTGCAGTGGCACGATCTAGGC
TCACTGCATGCTC. The deletion encompasses
33,568 bp and includes exons 5 to 10 of SLC3A1
and exons 9 to 14 of PREPL (figure 1G, deletion J).
A 278-bp fragment at the border of the deletion was
82% complementary in SLC3A1 and PREPL. Within
this fragment, a 22-bp fragment, beginning exactly at
Figure 2 PREPL expression (A–E) and EP ultrastructure (F–I)
(A, B) PREPL (green signal) and a-bungarotoxin (red signal) localization in control muscle fibers and endplates (EPs). (C) Merged image of A and B. (D) PREPL
localization in patient muscle fibers and EPs. Note absence of PREPL expression. (F) Ultrastructure of well-developed EP harboring abundant synaptic
vesicles. Asterisks indicate vesicles focused on active zones. (G) Normal density and distribution of the acetylcholine receptor on junctional folds revealed by
peroxidase-labeled a-bungarotoxin. (H) Abnormal nerve terminal filled with neurofilaments surrounded by degenerate organelles. (I) An EP harbors auto-
phagic vacuoles in the junctional sarcoplasm (X). A postsynaptic region is denuded of its nerve terminal (x). The asterisk indicates a nearby nerve sprout. Bar
in D 5 25 mm for panels A–E. Bars in F and G 5 0.5 mm; bar in H 5 1.3 mm; bar in I 5 2 mm.
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the breakpoint, was 100% complementary to SLC3A1
and PREPL. In addition, the patient harbors a paternally
inherited c.807delT (p.Met270X) mutation in PREPL
exon 6 (see figure 1F).
PREPL expression in muscle and at EPs. To ascertain
that PREPL expression was absent from the patient’s
muscle fibers and EPs, we immunostained frozen sec-
tions of patient and control muscles harboring EPs with
an antibody against the C-terminal region of PREPL
(green signal) and demonstrated AChR at the EPs with
rhodamine-labeled a-bungarotoxin (red signal). This
revealed PREPL in control muscle fibers and EPs
(figure 2, A–C) and its absence in the patient’s muscle
fibers and EPs (figure 2, D and E). Immunoblots of
extracts of patient and control muscles confirmed
absence of PREPL in the patient’s muscle (see figure e-2).
Structural studies. In frozen sections, the patient EPs
showed robust expression of AChR (figure 2E) and
acetylcholinesterase. It is interesting that in transverse
sections, the patient’s EPs appeared large relative to
the size of the muscle fibers (figure 2E), and in longi-
tudinal sections, the patient’s EPs were 20 to 22 mm
long (figure e-3), which was similar to the length of
EPs in adult control muscles (20.7 6 1.2 mm,
mean 6 standard error; n 5 17).
Qualitative inspection of electron microscopy im-
ages revealed well-developed EPs with nerve terminals
harboring abundant synaptic vesicles (figure 2F) re-
acting strongly for AChR (figure 2G). Quantitative
analysis of 66 regions of 35 EPs showed that the mean
nerve-terminal and postsynaptic areas were, respec-
tively, 75% and 66% of the corresponding adult con-
trol values. These findings are likely related to the
smaller size of the patient muscle fibers. The postsyn-
aptic membrane density was higher than normal. The
synaptic vesicle density in the nerve terminals was
normal (table 1). One EP displayed a degenerating
nerve terminal (figure 2H); another EP harbored
autophagic vacuoles in the junctional sarcoplasm
and an abandoned postsynaptic region (figure 2I).
Intracellular microelectrode studies and EP AChR
content. At age 6 months, the MEPP and MEPC am-
plitudes were reduced to approximately 40% of nor-
mal. The MEPC decay time constant was normal,
indicating normal AChR channel kinetics. The quan-
tal content of the EPP (m) was approximately half of
Table 1 Quantitative analysis of single EP regions
Patient (no.) Controls (no.) p
Nerve terminal area, mm2 2.93 6 0.28 (70 regions) 3.88 6 0.39 (63) ,0.01
Synaptic vesicle density, no./mm2 63 6 5.7 (32) 50.3 6 3.60 (32) NS
Postsynaptic area, mm2 7.01 6 0.38 (66) 10.6 6 0.79 (59) ,0.001
Postsynaptic membrane density, mm/mm2 6.27 6 0.22 (66) 5.83 6 0.25 (47) ,0.05
[125I]a-bungarotoxin binding sites per EPa 6.44 E6 4.7 E6 in 2-y-old control;
12.8 6 0.83 E6 (13 adults)
Abbreviations: EP 5 endplate; NS 5 not significant.
Values indicate mean 6 standard error. Numbers in parentheses indicate number of EP regions, except for a-bungarotoxin
binding sites, where the number indicates subjects.
a Two a-bungarotoxin molecules bind to each acetylcholine receptor.
Table 2 Microelectrode studies of neuromuscular transmission and a-bungarotoxin binding sites per EP
Patient (no. of EPs) Controls (no.) p
MEPPa 0.37 6 0.03 (14) 1.00 6 0.025 (165) ,0.001
MEPC, nAb 1.92 6 0.15 (10) 3.95 6 0.10 (79) ,0.001
MEPC decay time constantb 3.51 6 0.23 (10) 3.23 6 0.06 (79) NS
m at 1 Hzc 8 6 0.78 (17) 14.0 6 2.2 in 14-mo-old control (12);
adult controls: 29 6 2.2 (190)
,0.005
n (no. of quanta available for release) 90 6 16 (4) 230 6 14 (12) ,0.001
p (probability of quantal release) 0.11 6 0.24 (4) 0.15 6 0.21 (12) NS
Abbreviations: EP 5 endplate; MEPC 5 miniature EP current; MEPP 5 miniature EP potential; NS 5 not significant.
Values indicate mean 6 standard error. Numbers in parentheses indicate number of EPs, except for n in controls, where
they represent number of subjects.
aCorrected for membrane potential of 280 mV and fiber diameter of 50 mm; 30°C.
b280 mV; 25°C.
cCorrected for membrane potential of 280 mV, nonlinear summation, and non-Poisson release.
Neurology 82 April 8, 2014 5
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
that of a 16-month-old control. On increasing the
Ca21 concentration in the perfusing fluid from 2 to
5 mM, m increased by an amount comparable to that
observed in normal controls. The reduced m was due
to reduction of the number of quanta available for
release (n), whereas the probability of quantal release
(p) was normal. The number of [125I]a-bungarotoxin
binding sites per EP was higher than that of a 2-year-
old normal control (table 2).
DISCUSSION We here show that the myasthenic
symptoms in HCS are due to PREPL deficiency and
that isolated PREPL deficiency is a monogenic cause
of a novel myasthenic syndrome. The proband is com-
pound heterozygous for a paternal nonsense mutation
in PREPL (p.Met270X) and a maternal deletion muta-
tion involving PREPL and SLC3A1. Because this
patient retains a functional SLC3A1 allele, her pheno-
type is determined by loss of both PREPL alleles. Inter-
estingly, the borders of the SLC3A1-PREPL deletion
harbor a 278-bp region with high homology between
SLC3A1 and PREPL that would facilitate nonallelic
homologous recombination and provide a mechanism
for the novel deletion. That the patient also has growth
hormone deficiency indicates that PREPL is essential
for normal growth hormone secretion.
The structural and electrophysiologic features of
our patient differentiate the congenital myasthenic
syndrome caused by PREPL deficiency from all here-
tofore identified congenital myasthenic syndromes.
For example, the combined occurrence of low MEPP
amplitude at rest in the face of robust AChR expres-
sion, no kinetic abnormality in AChR, reduced quan-
tal release, and enlarged EP size excludes defects in
AChR subunit genes, RAPSN,MUSK, AGRN, ColQ,
ChAT, SCN4A, DOK7, GFPT1, DAPGT1, and in
other genes subserving protein glycosylation.20,21
The myasthenic features of the patient with isolated
PREPL deficiency and of our 3 patients with HCS
prompted us to treat them with pyridostigmine. That
only the 2 infants—the one with isolated PREPL defi-
ciency and patient HCS1—responded favorably, and
that they did not worsen when therapy was stopped
after 9 and 2 months, respectively, suggest spontaneous
improvement of the myasthenia with age. The reason
for this and why the older patients are refractory to
pyridostigmine await explanation.
A reduced postsynaptic response to ACh indicated
by the reduced amplitudes of the MEPP and MEPC
in the face of robust AChR expression and no kinetic
abnormality of AChR point to a reduced ACh con-
tent of the synaptic vesicles. This could stem from a
defect in presynaptic choline transport,22 ACh resyn-
thesis, as in EP choline acetyltransferase deficiency,11
the vesicular ACh transporter,23 or the vesicular pro-
ton pump.24 Because the phenotype with reduced
presynaptic choline transport is different,22 another
mechanism is more likely to be pathogenic. The
known function of PREPL is to act as an effector of
the clathrin-associated adaptor protein 1 (AP-1) by
binding to its m1A subunit to release AP-1 from tar-
get membranes.25 Because the trafficking of the vesic-
ular ACh transporter between the synaptic vesicle
membrane and the cytosol depends on AP-1,26
absence of PREPL provides a plausible explanation
for reduced filling of the synaptic vesicles with ACh.
A reduced number of quanta (n) available for
release with a normal probability (p) of release can
result from small synaptic contacts,27 paucity of synap-
tic vesicles,28 impaired transport of the synaptic vesicles
to the active zones, or a defect in the molecular
machinery governing exocytosis.29 Nerve terminal size
at single EP regions in our patient was only mildly
reduced, but the individual EPs were enlarged, the
synaptic vesicle density was in the high-normal range
(table 1), and abundant synaptic vesicles abutted on the
presynaptic active zones (figure 2A), pointing to a defect
in the late stages of exocytosis, for instance soluble
N-ethylmaleimide-sensitive factor atachment protein
receptor (SNARE)-dependent vesicle fusion. Enlargement
of the EPs might serve to compensate for reduced quantal
release for it also occurs in Lambert-Eaton syndrome in
which quantal release is markedly decreased (unpublished
observations by Andrew Engel).
Recently, the SNARE content of membranous
vesicles delivering cargo to and from the trans-Golgi
network was shown to depend on AP-1.30 Because
PREPL enhances the membrane dissociation of
AP-1,25 absence of PREPL may affect the SNARE
content of vesicles emerging from the trans-Golgi net-
work. However, it remains unclear how this would
reduce delivery of SNAREs to the primitive synaptic
vesicles assembled in the anterior horn cells for deliv-
ery to the nerve terminals by axonal transport.31,32
The degenerative changes observed at 2 EP regions
were of special interest because they suggest that
PREPL may also be required for maintaining normal
EP architecture. Because these changes were infre-
quent, they are unlikely to be clinically significant
at age 6 months, but the possibility exists that they
were more abundant in the neonatal period when
the patient’s weakness was most severe.
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